560082-53-3

Basic information

• Product Name: 6-BROMO-8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
• Synonyms: 6-BROMO-8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE;6-BROMO-8-FLUORO-4H-BENZO[1,4]OXAZIN-3-ONE;6-Bromo-8-fluoro-2,4-dihydro-1,4-benzoxazin-3-one;6-broMo-8-fluoro-3,4-dihydro-2H-1,4-benzoxazin-3- one
• CAS NO: 560082-53-3
• Molecular Formula: C8H5BrFNO2
• Molecular Weight: 246.03
• Mol File: 560082-53-3.mol

Chemical Properties

• Boiling Point: 356 °C at 760 mmHg
• Flash Point: 169.103 °C
• Appearance: /
• Density: 1.754 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly)
• PKA: 10.86±0.20(Predicted)
• CAS DataBase Reference: 6-BROMO-8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(560082-53-3)
• EPA Substance Registry System: 6-BROMO-8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(560082-53-3)

Safety Data

• Hazardous Substances Data: 560082-53-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-8-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one is used as a reactant for the preparation of benzoxazinone derivatives. These derivatives have been found to possess potent and selective nonsteroidal mineralocorticoid receptor antagonistic properties, making them valuable in the development of new drugs for the treatment of various medical conditions, such as hypertension and heart failure.
Used in Chemical Synthesis:
Due to its unique structural features, 6-Bromo-8-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one can be employed as a versatile building block in the synthesis of a wide range of chemical compounds. Its reactivity can be exploited in various chemical reactions, such as substitution, addition, and condensation, to generate a diverse array of molecules with potential applications in various fields, including pharmaceuticals, agrochemicals, and materials science.
Used in Research and Development:
6-Bromo-8-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one can also be utilized as a research tool in the study of the structure-activity relationships of benzoxazinone derivatives. By investigating the effects of various structural modifications on the biological activity of these compounds, researchers can gain valuable insights into the design and development of more effective and selective mineralocorticoid receptor antagonists.

InChI:InChI=1/C8H5BrFNO2/c9-4-1-5(10)8-6(2-4)11-7(12)3-13-8/h1-2H,3H2,(H,11,12)

Upstream product

• 320-76-3 2-fluoro-4-bromo-6-nitro-phenol 
• 943994-29-4 methyl 2-(4-bromo-2-fluoro-6-nitrophenoxy)acetate 
• 182499-89-4 5-Bromo-3-fluoro-2-hydroxyaniline 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 1454580-55-2 8-fluoro-6-[4-(4-fluorophenyl)-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-3-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 1454580-53-0 8-fluoro-6-[4-(4-fluorophenyl)-1-(4-methoxybenzyl)-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-3-yl]-2H-1,4-benzoxazin-3(4H)-one 
• 943994-30-7 6-acetyl-8-fluoro-2H-1,4-benzoxazin-3(4H)-one 

Relevant articles and documents

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

ANTIBACTERIAL COMPOUNDS

The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Tetrahydroquinoline analogues as muscarinic agonists

The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of ΡΒΚδ, and compounds that are dual inhibitors of both Btk and PI3Kδ. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3Kδ provides a therapeutic benefit to a patient having the disease.

Short and efficient synthesis of oxazinone-and thiazinone-containing bicyclic heteroaromatic aldehydes

Short and efficient route for the synthesis of oxazinone-and thiazinone-containing bicyclic heteroaromatic aldehydes, which involves the key step of palladium-catalyzed reductive carbonylation, is described. Overall routes for the synthesis of these aldehydes are short, versatile, and scalable with good yields of the product. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]

Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists

Mineralocorticoid receptor (MR) blockade has come into focus as a promising approach for the treatment of cardiovascular diseases such as hypertension and congestive heart failure. In order to identify a novel class of nonsteroidal MR antagonists that exhibit significant potency and good selectivity over other steroidal hormone receptors, we designed a novel series of benzoxazin-3-one derivatives and synthesized them from 6-(7H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazin-6-yl)-2H-1,4-ben-zoxazin-3(4H)-one (1a), high-throughput screening (HTS) hit compound. Our design was based on a crystal structure of an MR/compound complex and a docking model. In the course of lead generation from 1a, a 1,2-diaryl framework was characterized as a key structure with high binding affinity. On the basis of scaffold hopping and optimization studies, benzoxazin-3-one derivatives possessing 1-phenyl-3-trifluoromethylpyrazol-5-yl moiety at the 6-position were identified as a novel series of potent and selective MR antagonists. Among these compounds, 6-[1-(4-fluoro-2-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-5-yl]-2H-1,4-benzoxazin-3(4H)-one (14n) showed highly potent activity and good selectivity and also exhibited a significant antihypertensive effect in deoxycorticosterone acetate-salt hypertensive rats. On the basis of these results, compound 14n was progressed for further pharmacological evaluation. (Figure presented)

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.